Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.

Mark A SamaanSiddharth BirdiMaria Sierra MoralesSailish HonapAravind Gokul TamilarasanGeorgina CunninghamIoannis KoumoutsosShuvra RayJoel MawdsleySimon H C AndersonJeremy SandersonPeter M Irving

Published in: Frontline gastroenterology (2019)

Our findings demonstrate VDZ dose intensification to be effective at achieving clinical response in half of patients. Low baseline CRP and response at week 12 are potential predictors of week 24 response.

Keyphrases

end stage renal disease
randomized controlled trial
ejection fraction
prognostic factors
peritoneal dialysis
patient reported outcomes
human health